Tag: Gilead Sciences Inc
-
BioCryst is profitable. Now it wants to buy more rare disease drugs
Rare disease drug development is getting a boost from new funding models and a growing group of smaller biotech buyers.
-
CNBC Daily Open: Tariffs in spotlight — and Trump has a new name for a lake
President Donald Trump’s administration is reportedly mulling over new tariffs on chips, while Nvidia increases support for Chinese AI models.
-
FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients
The new pill is also aimed at people who are doing well on a single-tablet regimen, including Biktarvy, and want to switch to a new treatment.
-
The startup using AI to help rare disease families develop custom treatments
Nome uses AI and drug-development expertise to help rare disease families turn genetic diagnoses into potential paths toward treatment.
-
Court rules companies can’t import Gilead medications from overseas in blow to AFP health programs
A U.S. appeals court has ruled in favor of Gilead Sciences against companies known as alternative funding programs that import medicines from overseas.
-
Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio
Jazz Pharmaceuticals will acquire Actio Biosciences, Inc., a deal that expands Jazz’s pipeline and presence in rare epilepsy treatments.
-
The power of genetic testing: new screening methods are catching rare diseases before symptoms start
Genetic testing is helping doctors identify rare diseases earlier, opening the door to treatment options before symptoms appear.
-
CAMP4 advances rare disease treatment for SYNGAP1 into human trials
CAMP4 is preparing a Phase 1/2 trial of an experimental SYNGAP1 therapy, marking a major milestone for patients with the rare disease.
-
AstraZeneca may buck a decade of pharma strategy to buy U.S. scale
Reports of preliminary talks between AstraZeneca and Bristol Myers Squibb moved shares and reignited debate over Big Pharma consolidation.
-
AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb
The companies have discussed a potential merger over several months, the Financial Times reported on Sunday.
Latest News
Stay Connected
Categories
BBC News CNA CNBC CNN International Deutsche Welle (DW) Euronews France 24 General Global & European Specialized & Regional
Tags
amp Artificial intelligence Asia Breaking News: Business Breaking News: Markets Breaking News: Politics Breaking News: Technology Business business news cent china cup Donald J. Trump Donald Trump economy European Union fast football France germany Investment strategy iran Iran war markets news People per politics return russia said Singapore spain Sport Stock markets technology trump ukraine United States US-Israel attack on Iran 2026 video War in Ukraine World world cup World Cup 2026
About the Author
AF themes
Easy WordPress Websites Builder: Versatile Demos for Blogs, News, eCommerce and More – One-Click Import, No Coding! 1000+ Ready-made Templates for Stunning Newspaper, Magazine, Blog, and Publishing Websites.
Search the Archives
Access over the years of investigative journalism and breaking reports
You May Have Missed
